Program
Lithium
Also written as “lithium” and “lithium (mood stabilizer)”.
Its studies are mostly in Bipolar Disorder · Mania · Alcoholism, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 50 open or running | phase 4since Jun 29, 2009 | Apr 9, 2004 | none ahead |
| Hikma Pharmaceuticals | 40 open or running | no phasesince Sep 19, 2007 | Sep 19, 2007 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since Dec 9, 2024 | Dec 9, 2024 | none ahead |
Also a collaborator on its studies: quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 9, 2004First study: phase 3 study in Bipolar DisorderNew to AstraZenecaAstraZeneca · NCT00081380 · 710 enrolled · United States, Canada
- Apr 7, 2005Phase 3 study in Bipolar DisorderAstraZeneca · NCT00107731 · 710 enrolled · United States, Australia, Belgium and more
- Jun 16, 2005Phase 3 study in AlcoholismAstraZeneca · NCT00114686 · 350 enrolled · United States
- Mar 16, 2007Phase 3 study in ManiaAstraZeneca · NCT00448578 · 150 enrolled · China
- Sep 19, 2007Hikma Pharmaceuticals's first studies: 2 no phase studies in Bipolar DisorderNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT00602381, NCT00601575
- Jan 15, 20082 no phase studies in Bipolar DisorderHikma Pharmaceuticals · NCT00602394, NCT00601536
- Jun 29, 2009Phase 4 study in ManiaAstraZeneca · NCT00931723 · 356 enrolled · Belgium, Bulgaria, Germany and more
- Dec 9, 2024Bristol-Myers Squibb's first study: phase 1 study in Healthy VolunteersNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT06729970 · 133 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06729970Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Jan 23, 2026 | 133 |
| NCT00931723Mania · Belgium, Bulgaria, Germany and more | 4 | Completed | AstraZeneca | Nov 2010 | 356 |
| NCT00602394Bipolar Disorder · United States | – | Completed | Hikma Pharmaceuticals | May 2003 | 30 |
| NCT00601536Bipolar Disorder · United States | – | Completed | Hikma Pharmaceuticals | May 2003 | 29 |
| NCT00602381Bipolar Disorder · United States | – | Completed | Hikma Pharmaceuticals | Nov 2002 | 30 |
| NCT00601575Bipolar Disorder · United States | – | Completed | Hikma Pharmaceuticals | Oct 2002 | 30 |
| NCT00448578Mania · China | 3 | Completed | AstraZeneca | 150 | |
| NCT00114686Alcoholism · United States | 3 | Completed | AstraZeneca | 350 | |
| NCT00107731Bipolar Disorder · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | 710 | |
| NCT00081380Bipolar Disorder · United States, Canada | 3 | Completed | AstraZeneca | 710 |
How it is read
Names in the registry
- “Lithium”, 7 entries
- “lithium”, 2 entries
- “lithium (mood stabilizer)”, 1 entry
Conditions, from the studies’ own filings
- Bipolar Disorder, 6 studies
- Mania, 2 studies
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.